July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

June 04, 2025

Dog Exposure May Lower Genetic Eczema Risk

A large European study found that early-life dog exposure may reduce the genetic risk for atopic eczema, with lab results confirming a biological mechanism involving immune signaling in skin cells.

Conexiant

February 20, 2025

18-Year Neuroblastoma Remission in a Patient After GD2 CAR T-Cell Therapy

"She has never required any other therapy and is likely the longest-surviving patient with cancer who received [CAR T-cell] therapy."

Conexiant

January 23, 2025

Exploratory Metabolomic Study Identifies Potential SIDS Pathways

Potential biomarkers and metabolic pathways linked to sudden infant death syndrome were identified.

Conexiant